Literature DB >> 19301452

Transcatheter interatrial shunt closure as a cure for migraine: can it be justified by paradoxical embolism-risk-driven criteria?

Gianluca Rigatelli1, Paolo Cardaioli, Massimo Giordan, Fabio Dell'Avvocata, Gabriele Braggion, Mauro Chianaglia, Loris Roncon.   

Abstract

BACKGROUND: Some ongoing trials have suggested that closure of the patent foramen ovale (PFO) may reduce migraine symptoms. We sought to assess the safety and effectiveness of migraine treatment by means of PFO transcatheter closure using paradoxical embolism risk-driven criteria.
METHODS: We enrolled 75 patients (48 women and 27 men, mean age 40 +/- 3.7 years) who were referred to our center over a 12-month period for a prospective study to evaluate severe disabling migraine, despite antiheadache therapy and the PFO. Migraine Disability Assessment Score (MIDAS) was used to assess the incidence of migraine headache and severity. Criteria for intervention included all of the following: basal shunt, curtain shunt pattern on transcranial Doppler, presence of interatrial septal aneurysm, 3 to 4 class MIDAS score, symptomatic significant aura, coagulation abnormalities, migraine refractory to conventional drugs.
RESULTS: On the basis of the inclusion criteria, we shortlisted 20 patients (12 women, mean age 35 +/- 6.7 years, mean MIDAS score 38.9 +/- 5.8) for transcatheter closure of PFO and excluded the rest who were referred to the neurologist for medical therapy. The procedure was successful in all of the patients with no perioperative or in-hospital complications. After a mean follow-up of 10 +/- 3.1 months (range 6-14), all patients' migraine symptoms improved (mean MIDAS score 3.0 +/- 2.1, P < 0.03) with PFO complete closure in all patients on transesophageal and transcranial Doppler ultrasound.
CONCLUSION: In this small pilot series, we adopted the criteria which in our opinion best reflected the risk of paradoxical embolism in these patients. By adopting the proposed criteria, primary transcatheter closure of the PFO resulted in a significant reduction in migraine.

Entities:  

Mesh:

Year:  2009        PMID: 19301452     DOI: 10.1097/maj.0b013e31818599a7

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  3 in total

1.  Improving migraine by means of primary transcatheter patent foramen ovale closure: long-term follow-up.

Authors:  Gianluca Rigatelli; Fabio Dell'avvocata; Paolo Cardaioli; Massimo Giordan; Gabriele Braggion; Silvio Aggio; Roberto L'erario; Mauro Chinaglia
Journal:  Am J Cardiovasc Dis       Date:  2012-05-20

Review 2.  A systematic review of the psychosocial difficulties relevant to patients with migraine.

Authors:  Alberto Raggi; Ambra Mara Giovannetti; Rui Quintas; Domenico D'Amico; Alarcos Cieza; Carla Sabariego; Jerome Edmound Bickenbach; Matilde Leonardi
Journal:  J Headache Pain       Date:  2012-09-23       Impact factor: 7.277

3.  Patent Foramen Ovale and Migraine: Casual or Causal.

Authors:  Adrija Hajra; Dhrubajyoti Bandyopadhyay
Journal:  N Am J Med Sci       Date:  2016-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.